Paget’s disease of bone: an update on epidemiology, pathogenesis and pharmacotherapy

L Gennari, D Rendina, T Picchioni, S Bianciardi, M Materozzi, R Nuti, D Merlotti

Research output: Contribution to journalArticle

Abstract

Introduction: Paget’s disease of bone (PDB) is a chronic bone disorder, which affects middle-aged or older adults and results in enlarged and deformed bones in one or more skeletal regions. Family history has been reported in up to 40% of cases, suggesting a consistent genetic predisposition. At affected sites, the characteristic feature of PDB is an increased resorption followed by an increased bone formation, producing a disorganized and structurally abnormal bone. Consequently, bone pain, arthritis, deformities, and fractures can occur. In less than 1%, neoplastic degeneration in osteosarcoma, or giant cell tumor has been described at PDB sites. Areas covered: We provide a contemporary overview of the epidemiology, pathogenesis and treatment of PDB. Expert opinion: While recent epidemiological evidence indicates a decreasing prevalence and severity of PDB, over the past two decades there have been consistent advances on the genetic mechanisms of PDB. It is now clear that PDB is a genetically heterogeneous disorder, with at least three different genes (SQSTM1, ZNF687, FKBP5) involved in the classic form and four additional genes identified in PDB-related syndromes. The clinical management of PDB has also evolved, with the development of the most potent aminobisphosphonate, zoledronic acid, which allows long-term remission in the majority of patients. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
Original languageEnglish
Pages (from-to)485-496
Number of pages12
JournalExpert Opinion on Orphan Drugs
Volume6
Issue number8
DOIs
Publication statusPublished - 2018

    Fingerprint

Cite this

Gennari, L., Rendina, D., Picchioni, T., Bianciardi, S., Materozzi, M., Nuti, R., & Merlotti, D. (2018). Paget’s disease of bone: an update on epidemiology, pathogenesis and pharmacotherapy. Expert Opinion on Orphan Drugs, 6(8), 485-496. https://doi.org/10.1080/21678707.2018.1500691